Soluble Guanylate Cyclase Contribute Genetic Susceptibility to Essential Hypertension in the Han Chinese Population

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2020 Jan 14

PMID 31930021

Citations 3

Authors

Yan Chen

Lijun Zhu

Zhengmei Fang

Yuelong Jin

Chong Shen

Yingshui Yao

Chengchao Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Animal study found that soluble guanylate cyclase (sGC) plays an important role in development of hypertension (HT) by affecting the NO-sGC-CGMP signaling pathway. This study aims to evaluate the association of sGC with essential hypertension (EH) in the Han Chinese population.

Methods: This case-control study included 2,012 hypertensive cases and 2,210 controls, and 6 tagging single nucleotide polymorphisms (SNPs) were selected (rs3806777, rs3806782, rs3796576 and rs7698460 in , as well as rs2229202 and rs1459853 in ). Then the association of the six SNPs with EH was further evaluated in this study.

Results: The results indicated that the A/A genotype of rs1459853 in was associated with higher HT risk, and the odds ratio (OR) of its recessive model was 1.191 (P=0.044). After adjusting for covariates, the association was still significant. Further stratification analyses showed that rs1459853 in non-drinking subjects and rs7698460 in women were associated with EH. In the follow-up study, rs1459853 were related to increased HT risk in men and smoker subjects. In adolescents, rs2229202 that in had significant association with prehypertension (Pre-HT), HT, and prehypertension with hypertension (Pre-HT + HT). After adjusted for covariates, the association was remaining significant. And in girls, rs3806782 was significantly connected with HT and Pre-HT + HT.

Conclusions: Overall, our findings suggest that sGC may contribute to the genetic susceptibility to EH, and it was validated for the first time in adolescents.

Citing Articles

The Guanylate Cyclase Soluble Subunit Alpha-1 Deficiency Impairs Angiogenesis in Zebrafishes and Mice: In Vivo and In Vitro Studies.

Luo M, Mo D, Li J, Liu L, Li X, Lin J Mol Neurobiol. 2025; .

PMID: 39994159 DOI: 10.1007/s12035-025-04763-2.

Beyond eNOS: Genetic influence in NO pathway affecting drug response.

Esposito A, Cotta Filho C, Lacchini R Genet Mol Biol. 2022; 45(3 Suppl 1):e20220157.

PMID: 36264109 PMC: 9583294. DOI: 10.1590/1678-4685-GMB-2022-0157.

Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology.

Petraina A, Nogales C, Krahn T, Mucke H, Luscher T, Fischmeister R Cardiovasc Res. 2021; 118(9):2085-2102.

PMID: 34270705 PMC: 9302891. DOI: 10.1093/cvr/cvab240.

Left heart function evaluation of patients with essential hypertension and paroxysmal atrial fibrillation by two-dimensional speckle tracking imaging combined with real-time three-dimensional ultrasound imaging.

Jiang F, Chen Y, Wu L, Zhang Y, Liu J, Sun X J Thorac Dis. 2021; 13(1):322-333.

PMID: 33569212 PMC: 7867826. DOI: 10.21037/jtd-20-3577.

References

Kim M, Kim M, Yoo H, Shon J, Lee J . Associations between hypertension and the peroxisome proliferator-activated receptor-δ (PPARD) gene rs7770619 C>T polymorphism in a Korean population. Hum Genomics. 2018; 12(1):28. PMC: 6006737. DOI: 10.1186/s40246-018-0162-6. View

Venema R, Venema V, Ju H, Harris M, Snead C, Jilling T . Novel complexes of guanylate cyclase with heat shock protein 90 and nitric oxide synthase. Am J Physiol Heart Circ Physiol. 2003; 285(2):H669-78. DOI: 10.1152/ajpheart.01025.2002. View

Falkner B, Daniels S . Summary of the Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Hypertension. 2004; 44(4):387-8. DOI: 10.1161/01.HYP.0000143545.54637.af. View

Lopez-Farre A, Rodriguez-Feo J, Gomez J, Fortes J, de Andres R, Rico L . Reduction of the soluble cyclic GMP vasorelaxing system in the vascular wall of stroke-prone spontaneously hypertensive rats: effect of the alpha1 -receptor blocker doxazosin. J Hypertens. 2002; 20(3):463-70. DOI: 10.1097/00004872-200203000-00022. View

Belik J . Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Curr Opin Investig Drugs. 2009; 10(9):971-9. View

Stranges S, Wu T, Dorn J, Freudenheim J, Muti P, Farinaro E . Relationship of alcohol drinking pattern to risk of hypertension: a population-based study. Hypertension. 2004; 44(6):813-9. DOI: 10.1161/01.HYP.0000146537.03103.f2. View

Jo B, Choi S . Introns: The Functional Benefits of Introns in Genomes. Genomics Inform. 2016; 13(4):112-8. PMC: 4742320. DOI: 10.5808/GI.2015.13.4.112. View

Friebe A, Mergia E, Dangel O, Lange A, Koesling D . Fatal gastrointestinal obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclase. Proc Natl Acad Sci U S A. 2007; 104(18):7699-704. PMC: 1863512. DOI: 10.1073/pnas.0609778104. View

Lu X, Wang L, Lin X, Huang J, Gu C, He M . Genome-wide association study in Chinese identifies novel loci for blood pressure and hypertension. Hum Mol Genet. 2014; 24(3):865-74. PMC: 4303798. DOI: 10.1093/hmg/ddu478. View

10.

Ehret G, Munroe P, Rice K, Bochud M, Johnson A, Chasman D . Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011; 478(7367):103-9. PMC: 3340926. DOI: 10.1038/nature10405. View

11.

Rippe C, Zhu B, Krawczyk K, van Bavel E, Albinsson S, Sjolund J . Hypertension reduces soluble guanylyl cyclase expression in the mouse aorta via the Notch signaling pathway. Sci Rep. 2017; 7(1):1334. PMC: 5430981. DOI: 10.1038/s41598-017-01392-1. View

12.

Pradhan A, Manson J, Rifai N, Buring J, Ridker P . C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286(3):327-34. DOI: 10.1001/jama.286.3.327. View

13.

Fairbrother W, Yeo G, Yeh R, Goldstein P, Mawson M, Sharp P . RESCUE-ESE identifies candidate exonic splicing enhancers in vertebrate exons. Nucleic Acids Res. 2004; 32(Web Server issue):W187-90. PMC: 441531. DOI: 10.1093/nar/gkh393. View

14.

Beckman J, Grazul-Bilska A, Johnson M, Reynolds L, Redmer D . Isolation and characterization of ovine luteal pericytes and effects of nitric oxide on pericyte expression of angiogenic factors. Endocrine. 2006; 29(3):467-76. DOI: 10.1385/endo:29:3:467. View

15.

Buys E, Sips P, Vermeersch P, Raher M, Rogge E, Ichinose F . Gender-specific hypertension and responsiveness to nitric oxide in sGCalpha1 knockout mice. Cardiovasc Res. 2008; 79(1):179-86. DOI: 10.1093/cvr/cvn068. View

16.

Michl P, Ramjaun A, Pardo O, Warne P, Wagner M, Poulsom R . CUTL1 is a target of TGF(beta) signaling that enhances cancer cell motility and invasiveness. Cancer Cell. 2005; 7(6):521-32. DOI: 10.1016/j.ccr.2005.05.018. View

17.

Al-Qattan K, Thomson M, Al-Mutawaa S, Al-Hajeri D, Drobiova H, Ali M . Nitric oxide mediates the blood-pressure lowering effect of garlic in the rat two-kidney, one-clip model of hypertension. J Nutr. 2006; 136(3 Suppl):774S-776S. DOI: 10.1093/jn/136.3.774S. View

18.

Wallace S, Guo D, Regalado E, Mellor-Crummey L, Bamshad M, Nickerson D . Disrupted nitric oxide signaling due to GUCY1A3 mutations increases risk for moyamoya disease, achalasia and hypertension. Clin Genet. 2016; 90(4):351-60. PMC: 4949143. DOI: 10.1111/cge.12739. View

19.

Wang L, Shen C, Yang S, Chen Y, Guo D, Jin Y . Association study of NOS3 gene polymorphisms and hypertension in the Han Chinese population. Nitric Oxide. 2015; 51:1-6. DOI: 10.1016/j.niox.2015.09.004. View

20.

Erdmann J, Stark K, Esslinger U, Rumpf P, Koesling D, De Wit C . Dysfunctional nitric oxide signalling increases risk of myocardial infarction. Nature. 2013; 504(7480):432-6. DOI: 10.1038/nature12722. View